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Mesenchymal stem cells (MSCs) are an adult stromal cell
population possessing potent differentiation capacity
and a potential for use across major histocompatibility
complex barriers. Although allogeneic MSCs have potent
immunosuppressive properties, evidence also suggests
that they elicit a weak allogeneic immune response.
However, the effect of induced differentiation on the
immunosuppressive ability and immunogenicity of
allogeneic MSCs is a potential obstacle when applying
MSCs in tissue replacement therapies. These concerns
will be explored in this review, with particular emphasis
on changes in the cell surface expression of immunogenic
markers, changes in the secretion of immunosuppressive
molecules and in vivo functional benefits of the cell
therapy. We review the literature from a translational point
of view, focusing on pre-clinical studies that have utilised
and analysed the effects of allogeneic immune responses
on the ability of allogeneic MSCs to regenerate damaged
tissue in models of bone, heart and cartilage defects.addition to eliciting a weak cellular and humoral allogen-Introduction
Organ transplantation, as a medical procedure to replace
a damaged or defective organ, has been performed for
over 100 years. Numerous organs and tissues are now
routinely transplanted, including heart, kidney, islets,
liver, lung, cornea and skin [1]. The immune response
to, and consequent rejection of, allogeneic organ and
tissue grafts has always been a major issue and numer-
ous strategies have been developed to inhibit immune
responses, including irradiating the recipient, immuno-
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2014[1-3]. Despite the effectiveness of these treatment mo-
dalities, many transplanted organs still undergo acute
and chronic immune-mediated rejection episodes that
have drastic consequences for the survival and general
health of the patient [4].
Because of the immunological difficulties associated
with allogeneic transplantation, mesenchymal stem cells
(MSCs) have the potential to be an attractive tissue
replacement therapy for a number of reasons. MSCs are
multipotent cells that can be readily isolated from a
number of adult tissues, including bone marrow, umbil-
ical cord blood, adipose tissue and placenta. They have
been well documented to differentiate into osteogenic,
adipogenic and chondrogenic lineages in vivo, with evi-
dence also supporting an ability to differentiate into car-
diomyocyte, endothelial, hepatocyte and neural lineages
[2,5-13]. Differentiated MSCs (dMSCs) could be used
in tissue engineering- and regenerative medicine-based
approaches to treat a number of conditions.
In addition to their differentiation capacity MSCs are
defined by their ability to suppress immune responses in
eic immune response (here referred to as low immuno-
genicity) [2,14]. These immune properties of MSCs can be
attributed to a combination of low expression of immu-
nogenic cell surface molecules and secretion of several
immunosuppressive molecules. MSCs from numerous
sources and species have been shown to express low levels
of major histocompatibility complex class I (MHCI)
proteins on their cell surface as well as low levels of co-
stimulatory molecules, such as CD80 and CD86; add-
itionally, in the resting state, MSC express no major
histocompatibility complex class II (MHCII) proteins
[5-7,9,14,15]. These properties contribute to the so-
called hypo-immunogenicity of MSCs. The immunosup-
pressive ability of MSCs is attributed to their secretion
of several immunomodulatory molecules, such as pros-
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gene-protein 6, that can interfere with proliferation,
activation and effector function of many cells of the
immune system, including CD4+ and CD8+ T cells,
natural killer cells, B cells and antigen presenting cells
[5,6,16-21]. MSCs are also capable of increasing the
population of regulatory T cells [22]. This immunosup-
pressive ability has been reported to be cell contact
dependent and induced in vivo by activation of the cells
through encountering inflammatory cytokines such as
IFN-γ [21,23].
Allogeneic MSCs from young healthy donors are an
attractive source of regenerative cells for the treatment of
degenerative diseases with an inflammatory component.
As MSCs possess potent immunomodulatory properties
and an ability to differentiate into several lineages, there is
potential for allogeneic 'off the shelf' tissue engineering
solutions using these cells. These treatment options would
significantly decrease costs, reduce the number of proce-
dures patients must undergo and provide cells from young
healthy donors that may show higher efficacy than cells
from aged individuals [24]. Although evidence exists to
suggest MSC immunomodulatory properties may differ
depending on the tissue from which they are sourced [25]
or by contact with serum [26], there is no information dir-
ectly comparing the immune profile of allogeneic dMSCs
from different sources or after contact with serum. These
important issues should be investigated in future studies.
With the increasing number of clinical trials utilising allo-
geneic MSCs for acute and chronic diseases, a compre-
hensive understanding of the impact of differentiation on
the immunological profile of MSCs is essential.
Clinical application of allogeneic MSCs could take the
form of ex vivo differentiation of the MSCs followed by
administration to the damaged area or administration of
undifferentiated MSCs that subsequently undergo differ-
entiation in situ. Highly prevalent acute and chronic dis-
eases for which current treatments are suboptimal, such
as myocardial infarction (MI; prevalence of 3.2% of US
population in 2009) and osteoarthritis (OA; 27 million
people in US with clinical grade OA), are potential targets
for allogeneic dMSC therapy. In the context of available
evidence [12,13] the focus of this review will be on im-
mune responses to and therapeutic potential of allogeneic
MSCs differentiated into osteogenic, chondrogenic and
cardiomyocyte lineages [27,28].
Allogeneic mesenchymal stem cells in bone
regeneration
Allogeneic MSCs have been proposed for use in the re-
pair of critical size bone defects as well as a treatment
for osteogenesis imperfecta (OI) [11,29-32]. With the
field moving increasingly towards allogeneic cell thera-
peutic modalities [33], for reasons alluded to earlier, theimmunogenic potential of donor-derived ex vivo osteo-
genically primed or in vivo osteogenically differentiated
MSCs must be highlighted.
A number of pre-clinical studies focusing on the func-
tional benefits of allogeneic MSC implantation in bone
regeneration have produced contrasting results on rep-
arative outcomes, as can be seen in Table 1. Kang and
colleagues [31] demonstrated that implantation of undif-
ferentiated allogeneic or autologous MSCs comparably
supported the development of de novo bone without
lymphocytic infiltration. Similarly, Liu and colleagues [7]
and Arinzeh and colleagues [32] implanted ex vivo osteo-
genically differentiated cells in vivo in a leporine and
canine model, respectively, and found that these cells in-
corporated into the host tissue, functioned as osteoblasts
and resided in situ for at least 28 days without overt signs
of rejection such as hypercellularity. In contrast to these
data, however, it has been reported by others that im-
planted allogeneic MSCs require immunosuppressive treat-
ment to survive and differentiate in vivo, and are rapidly
cleared by infiltrating immune cells in the absence of such
immunosuppression [34,35]. Additionally, expression of
immunogenic molecules such as Swine leukocyte antigen-I
(SLA-I) on differentiating allogeneic porcine MSCs was
shown to reduce the in vivo efficacy of the treatment when
compared to allogeneic MSCs that had SLA-I knocked
down [36]. Wang and colleagues [37] showed that in vitro
cultured ovine MSCs maintain MHCI expression at similar
levels before and after osteogenic differentiation, while
osteogenic differentiated ovine and leporine MSCs are
negative for MHCII and fail to stimulate proliferation in
allogeneic leukocyte proliferation assays [7,37]. However,
these MHCII-negative cells retain a rich deposit of MHCII
mRNA in the cytoplasm that is rapidly translated and pre-
sented on the cell surface upon stimulation with IFN-γ
[38]. This has been confirmed in vivo where implanted
allogeneic osteogenically primed MSCs upregulate surface
expression of MHCII, pointing to a potentially increased
immunogenic phenotype when these cells are exposed to
an inflammatory environment [7].
In summary, contrasting pre-clinical outcomes in rela-
tion to the immunogenicity of osteogenically primed
MSCs have been reported, indicating the need for more
powerful pre-clinical studies to be completed before a
definitive conclusion on the potential of allogeneic MSCs
for bone tissue regeneration can be made.
Most importantly, the osteo-integration, differentiation
and immune acceptance of transplanted allogeneic MSCs
in humans must be considered. Allogeneic MSCs have
begun to be administered clinically to treat OI, necessitat-
ing the homing, integration and function of allogeneic cells
within the host. In contrast to the pre-clinical studies
outlined above, MSCs were administered intravenously.
Horwitz and colleagues [30] treated six patients with two
Table 1 Summary table of differentiated allogeneic MSC in bone regeneration models
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http://stemcellres.com/content/5/4/99transfusions, initially 1 million cells/kg and then 5 million
cells/kg 8 to 21 days later. No patient exhibited symptoms
of immune rejection, while five of the six children demon-
strated persistent engraftment of the transplanted cells
within the host tissue. Engraftment, even at low levels, re-
sulted in clinically significant improvement in mineralized
tissue deposition. However, it is not clear from this study if
the engrafted cells differentiated into osteogenic lineages
[30]. Le Blanc and colleagues [29] later transplanted allo-
geneic human foetal liver MSCs at 10 weeks gestation
in utero to a foetal recipient diagnosed with OI. Post-natal
observation at 9 months confirmed the engraftment and
functional differentiation of these transplanted cells via
expression of osteocalcin and bone sialoprotein. There was
no immunological reaction, either in vivo or in ex vivo re-
stimulation assays for up to 10 years. Over time, however,
allogeneic cells could no longer be detected and the func-
tional benefits observed in the months after treatment
were lost. A second infusion of the same donor cells was
administered, which was shown not to elicit an immune
response, and the patients’ growth was restored [39]. Al-
though direct comparison of results of pre-clinical and
clinical studies is complicated by the use of different
administration routes, the data gathered thus far indicate
that human allogeneic transplanted MSCs are capable of
homing to osseous tissue, integrating with the host and
maturing into functional osteoblasts without systemic im-
mune rejection.
Allogeneic mesenchymal stem cells in cardiac
regeneration
MI occurs as a result of loss of blood flow to an area of
the myocardium, resulting in ischemia and degeneration
of the muscle, leading to loss of cardiac function and po-
tentially death [40]. MSCs have therapeutic potential in
MI due to their secretion of paracrine regenerative and
pro-angiogenic factors, their homing ability and their
capacity to differentiate into cardiomyocytes, smooth
muscle and vascular endothelial lineages [40,41]. How-
ever, due to the fact that MI is a sudden event and an
immediate treatment may be necessary for an effective
outcome, allogeneic MSC therapy may be the ideal treat-
ment for MI [6].
As allogeneic in vitro cultured MSCs administered to
the area of an MI have the capacity to differentiate to
endothelium, smooth muscle and cardiac muscle, a thor-
ough understanding of the host immune response to
these newly differentiated cells is required before their
translation to the clinic. To date, allogeneic undifferenti-
ated MSCs have been administered in several pre-
clinical models of MI. While many of these studies did
not examine immunological parameters, as can be seen
in Table 2, they showed that MSCs are capable of en-
graftment into the damaged myocardium, specifically inthe infarct and border zones [42-46]. These engrafted
cells have been shown, in several separate studies, to
express markers of cardiac muscle, smooth muscle and
vascular endothelium, such as MF-20, troponin I, vascular
endothelium growth factor and von Willebrand factor
[6,40,44-46]. In addition to expressing markers of myocar-
dium, 5-azacytidine-treated MSCs have also been shown to
upregulate expression of immunogenic MHCI and MHCII
molecules. When these pre-treated allogeneic MSCs were
administered to an infarcted myocardium, they were recog-
nised by the immune system and quickly cleared from the
area with an accompanying loss of beneficial effects [47].
Several reports have indicated that allogeneic undifferen-
tiated MSC administration to infarcted myocardium results
in improved recovery of cardiac functional parameters
such as left ventricular ejection fraction at early time points
up to 3 months after administration [6,44-48]. However,
as pre-differentiated MSCs have been shown to become
strongly immunogenic, a major concern is that these ad-
ministered allogeneic undifferentiated MSCs may differen-
tiate in situ and develop a more immunogenic phenotype
that could result in immune cell infiltration in the heart,
clearance of the cells and loss of the functional benefits
of the therapy. In order to determine the immunological
effect of in situ differentiation on allogeneic MSCs, it is
necessary to follow the consequences of allogeneic MSC
therapy, both immunologically and functionally, for up to a
year [49].
In a rat MI model undifferentiated allogeneic MSCs
were shown to engraft, provide functional improvement
for up to 3 months and differentiate into vascular endo-
thelium, smooth muscle and cardiomyocytes. Huang and
colleagues [6] showed that these cells elicit an allogeneic
antigen-specific immune response, demonstrated by the
presence of specific anti-donor antibodies directed against
differentiated but not undifferentiated MSCs at 5 weeks
post-administration that was accompanied by elimination
of allogeneic cells at the same time-point. When the func-
tional benefits of the therapy were determined, there
was no difference between syngeneic and allogeneic MSC
treatment at 3 months post-administration; however, after
6 months allogeneic MSC-treated animals had signifi-
cantly reduced cardiac function compared to syngeneic
MSC-treated animals [6]. Follow-up studies indicate that
the rejection of allogeneic MSCs might be facilitated by
the loss of PGE2 expression in the cells as they differenti-
ate [5,18,49]. PGE2 is essential for expression of chemo-
kines such as CCL5 and CCL12 that attract T cells to the
MSCs and result in an increased proportion of regulatory
T cells [18]. It was found that when allogeneic MSCs were
administered to an MI together with extracellular PGE2
the survival of the cells was maintained, rejection was
prevented and the functional benefits of the therapy were
restored [18].
Table 2 Summary table of differentiated allogeneic MSC in myocardial regeneration models
Paper Model In vitro immunogenicity In vitro
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ical trials of MI, although it was not determined if these
cells differentiated in situ. No significant adverse events
were observed up to 12 months after administration and
cell-treated patients showed a significant increase in left
ventricular ejection fraction compared to placebo, which
was maintained throughout the 12-month observation
period. Additionally, a trend towards improved cardiac
remodelling was observed in cell-treated patients [50].
However, longer follow-up times will be required to de-
termine if the benefit of allogeneic MSC therapy for MI
can be maintained in the long-term and also to deter-
mine any additional immunological effects if a second
cell administration is required.
Allogeneic mesenchymal stem cells in cartilage
regeneration
OA is a degenerative disease characterized by articular
cartilage loss and synovial inflammation. While some re-
generation of cartilage is possible in childhood, the regen-
erative capacity is lost with time and is nearly completely
absent after 60 years of age [51]. The use of differentiated
allogeneic MSCs is envisioned based on their ability to
differentiate into cartilage [52], their ability to modulate
inflammation by the release of anti-inflammatory fac-
tors [16,19-21] and their low levels of MHC and co-
stimulatory proteins [14]. Prior to their clinical use, and
similar to the use of allogeneic MSCs for bone defects and
cardiac repair, a comprehensive understanding of the allo-
geneic immune response to chondrogenically differenti-
ated allogeneic MSCs is crucial for elucidating the success
of stem cell-based cartilage repair in vivo. A small number
of studies (outlined in Table 3) have addressed the impact
of chondrogenic differentiation on the immunosuppressive
ability of allogeneic MSCs from different sources. Al-
though Zheng and colleagues [53] showed that dMSCs re-
tain their ability to suppress allogeneic immune responses
in a model of rheumatoid arthritis, other studies have
shown an altered ability to suppress immune responses
in vitro [5,54]; Chen and colleagues [54] showed that
chondrogenically differentiated MSCs, in contrast to un-
differentiated allogeneic MSCs, were unable to suppress
dendritic cell function. On the contrary, they showed that
dMSCs induced dendritic cell maturation and the human
peripheral blood leukocyte-stimulating and cytotoxicity-
inducing effects of MSCs increased between four- and
eight-fold in differentiated cultures compared to undiffer-
entiated MSCs. Similarly, we showed significant loss of
ability to suppress activated CD4+ and CD8+ T cells,
which was accompanied by inhibition of PGE2 and nitric
oxide [5].
The limited number of studies [5,54,55] addressing the
important issue of immunogenicity hinder our under-
standing of the consequences of allogeneic MSCdifferentiation on therapeutic efficacy in functional
models of cartilage repair. Chondrogenic differentiation
has been shown to increase the immunogenicity of
MSCs and many studies have shown increases in the ex-
pression of MHCI, MHCII, CD80 and CD86 [5,54,55].
We recently addressed in vivo immunogenicity and ob-
served enhanced T-cell and innate immune responses
following subcutaneous implantation of chondrogeni-
cally differentiated fully allogeneic rat MSC [5]. Using
an ex vivo re-stimulation assay, detectable sensitized
T-cell responses were seen in animals 6 weeks post-
implantation with chondrogenically differentiated MSCs,
which was accompanied by increased generation of
donor-specific antibodies. Interestingly, while these re-
sponses were prevented by encapsulation in the case of
undifferentiated allogeneic MSCs, encapsulation did not
prevent immune responses generated against chondro-
genically differentiated MSCs [5]. These findings are also
relevant for spontaneous differentiation of allogeneic un-
differentiated MSCs in vivo and may explain discrepan-
cies between studies using undifferentiated MSCs as a
therapeutic in models of OA. In fact, a recent study
showed that undifferentiated fully allogeneic MSCs lose
their immunosuppressive properties and this compro-
mises their ability to influence the course of collagen-
induced arthritis [56].
Conclusion
Due to the inherent lack of native regeneration in bone,
heart and cartilage tissues, regenerative medicine-based
approaches hold great therapeutic promise [6,30,51].
MSCs, as regenerative cells, are attractive for therapeutic
use in these diseases due to their ease of isolation and
culture and their ex vivo and in situ differentiation cap-
acities. However, cell therapy using autologous cells is a
time-consuming, expensive process with other disadvan-
tages such as donor site morbidity and quality issues
with using cells from aged patients [6,31]. For these rea-
sons allogeneic MSC therapy in the context of regenera-
tive medicine must be investigated pre-clinically with an
ultimate objective of translating such therapies to the
clinic.
Important issues raised during this review focus upon
the potential changes to the potent immunomodulatory
properties of MSCs that occur after differentiation of these
cells. While some of the literature appears contradictory,
there is evidence that the secretory profile of MSCs is al-
tered as they differentiate [5,18]. Although this requires a
more thorough analysis of the full secretome of MSCs dif-
ferentiated into various lineages, there is already convin-
cing experimental evidence that differentiation-associated
reduction in the secretion of immunomodulatory factors
such as PGE2 may have adverse effects on the survival of
the allogeneic graft in vivo and ultimately the reparative
Table 3 Summary table of differentiated allogeneic MSC in cartilage regeneration
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cells and the subsequent immune response is a critical
problem for solid organ transplantation mediated by the
presence of immunologically relevant surface proteins
such as MHCI, MHCII and co-stimulatory molecules on
the transplanted cells [57]. Many of the studies we have
reviewed here point to an increase in expression of these
immunogenic molecules on the cell surface of MSCs
as they differentiate (Figure 1) [5-7]. Nevertheless, other
studies have provided evidence suggesting no increased
immunogenicity or MHC upregulation for other lineages,
such as hepatocytes and neurons [12,13]. To date, how-
ever, insufficient pre-clinical data are available, suggest-
ing further studies are required to conclusively show
changes in immune responses after differentiation into
these lineages.As evidenced in the majority of studies reviewed
here, heightened immune responses may be induced by
dMSCs in vivo. Several potential strategies could con-
ceivably be employed to reduce the immunogenicity of
the cells or increase their immunosuppressive ability.
Such approaches could include addition of PGE2 [18] to
restore the immunosuppressive ability, which has shown
some promise in pre-clinical studies. In recent years pre-
treatment of MSCs with inflammatory cytokines such
as IFN-γ has shown that these pre-treated MSCs have
ncreased immunosuppressive ability in vivo [58]. Pre-
treating undifferentiated MSCs or dMSCs prior to im-
plantation may improve the immunosuppressive function
of these cells in vivo. Encapsulation of dMSCs in semi-
permeable membranes to shield the cells has the potential
to protect cells from immune cell and complement attack,
Figure 1 The impact of osteogenic, chondrogenic and myocardial differentiation on immunogenicity of allogeneic mesenchymal stem
cells. Changes and responses to allogeneic mesenchymal stem cells (MSCs) as they differentiate in vitro (blue shaded areas) or in vivo (green
shaded areas) are represented. General immunological characteristics of MSCs are represented along with documented changes that take place
as they differentiate into osteogenic, chondrogenic and cardiomyocyte lineages. Changes to relevant molecules are indicated with up arrows
representing an increase, down arrows representing a decrease and an equals sign representing no change in the indicated parameter. CTL,
cytotoxic T lymphocyte; DC, dendritic cell; dMSC, differentiated MSC; Ig, immunoglobulin; MHCI, major histocompatibility complex class I; MHCII,
major histocompatibility complex class II; MSC, mesenchymal stem cell; NO, nitric oxide; PBL, peripheral blood leukocyte; PGE2, prostaglandin E2.
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atic islets [59]. Some data also show promise for such
techniques where dMSCs were implanted in vivo [5].
Other potential approaches to improve allogeneic
dMSC transplant survival in vivo could be achieved by
genetic knockdown of immunogenic molecules such as
MHCI [36,60].
Further comprehensive analyses of the functional rele-
vance of increased expression of MHCI, MHCII and
co-stimulatory molecules on dMSCs in vivo need to be
undertaken, since not all studies to date are in agreement
on the issue of immunogenicity. In addition, a thorough
assessment of the impact of allo-immune responses on
therapeutic efficacy of dMSCs in fully allogeneic models
needs to be undertaken. This is especially true in the caseof chondrogenically differentiated allogeneic MSCs where
further pre-clinical experiments to assess the utility of
these cells in fully allogeneic cartilage regeneration models
are required.
What is clear is that several issues need to be addressed
before translation of allogeneic dMSC therapies to the
clinic: first, whether the allogeneic immune response hin-
ders the therapeutic efficacy of these cells and how we in-
terpret these findings; second, the long-term survival and
functional state of dMSCs in vivo; third, the paracrine ef-
fects of dMSCs in vivo; fourth, whether modification of
allogeneic dMSCs prior to transplantation is required; and
fifth, whether concomitant administration of immunosup-
pressive drugs is required [11]. The answers to these ques-
tions will undoubtedly unfold in due course.
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